HPB-092

News alerts, weekly reports and conference planners

Company:

Polymed Biopharma

Drug class:

FLT3 inhibitor, IRAK-4 inhibitor

Related drugs:

U2AF1 mutation	Acute Myelogenous Leukemia	U2AF1 mutation	Acute Myelogenous Leukemia	HPB-092 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) HPB-092 Sensitive : D AACR 2023 - 1wk	HPB-092 Sensitive: D – Preclinical AACR 2023 - 1 week HPB-092 Sensitive : D AACR 2023 - 1 week - (New D)
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	HPB-092 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) HPB-092 Sensitive : D AACR 2023 - 1wk	HPB-092 Sensitive: D – Preclinical AACR 2023 - 1 week HPB-092 Sensitive : D AACR 2023 - 1 week - (New D)

Associations
(2)